Journal of Clinical & Experimental Pharmacology

Robert Lubran

Biography

Dr. Lubran has been directing the Substance Abuse and Mental Health Services Administration (SAMHSA) Division of Pharmacologic Therapies since 1997. Under his leadership, SAMHSA has given responsibility for regulatory oversight and certification of more than 1,250 opioid addiction treatment centers treating in excess of 300,000 patients daily; implements the 2000 Drug Addiction Treatment Act resulting in the approval of more than 20,000 physicians to prescribe buprenorphine for the treatment of opioid dependence; published clinical guidelines on Managing Chronic Pain in Adults with or in Recovery from Substance Use Disorders and Medication Assisted Treatment for Opioid Addiction in Opioid Treatment Programs; provided grants to State Prescription Drug Monitoring Programs under the National All Schedules Prescription Electronic Reporting Act; supports the Federation of State Medical Boards efforts to update The Model Policy for the Use of Controlled Substances for the Treatment of Pain (2004). Prior to coming to SAMHSA in 1989, Mr. Lubran managed medical quality assurance, utilization management and peer review activities in the Department of Veterans Affairs Office of Quality Management. His other Federal assignments include positions with the National Institute of Mental Health and the Bureau of Health Planning and Resources Development. Before joining Federal service, Mr. Lubran was an analyst with the Mission Neighborhood Health Center in San Francisco, CA and the Executive Director of the Jefferson County Alcohol and Drug Abuse Center in Steubenville, Ohio. Mr. Lubran has advanced degrees in Public Administration from Golden Gate University, San Francisco, CA and Urban Affairs from Cleveland State University, Cleveland, OH. He is a graduate of Miami University, Oxford, Ohio.

Research Interest

Buprenorphine for the treatment of opioid dependence, Opioid Addiction, Prescription Drug Monitoring Programs.